Cutler Group LP Blueprint Medicines Corp Call Options Transaction History

Cutler Group LP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Jul 18, 2023	BUY	$42.2 - $66.37 $105,500 - $165,925	2,500 New	2,500 $33,000
Q1 2022 Apr 14, 2022	SELL	$54.1 - $110.08 $108,200 - $220,160	-2,000 Reduced 33.33%	4,000 $17,000
Q3 2020 Oct 27, 2020	SELL	$66.45 - $92.7 $119,610 - $166,860	-1,800 Reduced 23.08%	6,000 $46,000
Q3 2019 Oct 28, 2019	BUY	$72.9 - $101.41 $561,330 - $780,857	7,700 Added 7700.0%	7,800 $5,000
Q2 2019 Aug 09, 2019	SELL	$73.54 - $97.8 $14,708 - $19,560	-200 Reduced 66.67%	100 $1,000
Q1 2019 May 10, 2019	BUY	$48.7 - $86.6 $9,740 - $17,320	200 Added 200.0%	300 $2,000
Q3 2018 Nov 07, 2018	SELL	$58.91 - $78.32 $247,422 - $328,944	-4,200 Reduced 97.67%	100 $1,000
Q1 2018 May 11, 2018	BUY	$73.28 - $102.95 $14,656 - $20,590	200 Added 4.88%	4,300 $32,000
Q4 2017 Jan 17, 2018	BUY	$62.91 - $88.32 $232,767 - $326,784	3,700 Added 925.0%	4,100 $21,000
Q3 2017 Oct 17, 2017	BUY	$42.37 - $69.67 $16,948 - $27,868	400	400 $10,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.47B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.